Streptococcus Pyogenes Pharyngotonsillitis Clinical Trial
Official title:
Study to Investigate the Prophylactic Effect of Probiotic Streptococcus Salivarius K12 Supplementation Against Recurrent Streptococcus Pyogenes (GAS) Bacterial Pharyngotonsillitis in Children: A Randomized, Double-blind Controlled Clinical Trial
Recurrent Streptococcus pyogenes pharyngotonsillitis infection in children presents a significant health concern, characterized by frequent episodes of sore throat, fever, and swollen tonsils. These recurrent infections can lead to missed school days, discomfort, and potential complications if left untreated. Current treatment typically involves antibiotics to eradicate the bacterial infection. However, drawbacks exist with this approach, including the risk of antibiotic resistance, disruption of the gut microbiota, and potential adverse effects such as gastrointestinal upset or allergic reactions. Moreover, antibiotics do not prevent future episodes and may contribute to recurrent infections by disrupting the balance of the throat microbiome. Therefore, there is a growing interest in alternative approaches such as probiotics, which aim to support the body's natural defenses and restore microbial balance in the throat and oral cavity.
Recurrent Streptococcus pyogenes pharyngotonsillitis infection presents a persistent challenge in pediatric healthcare, often necessitating frequent antibiotic treatments with associated risks of antimicrobial resistance and disruption of the microbiota. Streptococcus salivarius K12, a commensal bacterium naturally inhabiting the human oral cavity, exhibits antimicrobial properties against pathogenic streptococci, including Streptococcus pyogenes. Moreover, S. salivarius K12 produces bacteriocin-like inhibitory substances (BLIS) that competitively inhibit the growth of pathogenic bacteria, potentially offering a prophylactic strategy to mitigate recurrent infections. This clinical trial aims to elucidate the scientific rationale underlying the use of probiotic S. salivarius K12 as a preventive measure against recurrent Streptococcus pyogenes pharyngotonsillitis in children aged 3-10 years, shedding light on its efficacy and safety in this vulnerable population. ;